|
1992
|
|
Issue
|
Vol.20 no.8 （643-654）
|
|
Title
|
Clinical study of triazolam on sleep
disorders in psychiatric aspect-Comparative
cross-over study with zopiclone-
|
|
Author
|
S.Tsujimaru et al.
|
We performed a cross-over study in which
triazolam was administrated for 2 weeks,
followed by a 2-week treatment with zopiclone,
or vice versa, in 27 patients with sleep
disorders in psychiatric field. The diagnoses
were schizophrenia in 10 patients, neurosis
in 7, depression in 6, neurotic insomnia
in 3 and organic psychosis in 1. Triazolam
treatment resulted in a global improvement
rate of 77.8% as compared to 63.0% for zopiclone
treatment and a utility rate (“very useful”+“useful”)
of 77.8% as compared to 63.0% for zopiclone
treatment. Both global improvement and utility
rates were thus significantly higher for
triazolam than zopiclone (p < 0.01).
Adverse reactions were reported by 2 patients
(7.4%) during triazolam treatment and 6
patients (22.2%) during zopiclone treatment,
but abnormal laboratory data were not observed.
Triazolam was found to be significantly
superior to zopiclone in the overall comparison
made taking all above indexes into account
(p < 0.01). All sleep parameters
except dream showed significant improvement
during both triazolam and zopiclone treatments
when compared to pre-treatment baselines.
The dream parameter improved significantly
only during triazolam treatment as compared
to the pre-treatment baseline. There were
significant differences between triazolam
and zopiclone regarding sleep onset and
sleep soundness. These findings indicate
that triazolam is superior to zopiclone
as a sleep inducer in terms of clinical
efficacy, adverse reactions, utility, sleep
onset, sleep soundness and dream when used
in the treatment of sleep disorders associated
with psychiatric disorders.
|
|
JPT
Online 
